Loading…
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $616M | $134M | $447M | $-25M | 69.0% | 87.3% | 1812.4% |
| 2024 | $329M | $50M | $23M | $-41M | 10.5% | 40.8% | 84.5% |
| 2023 | $234M | $26M | $13M | $-31M | 7.9% | 8290.0% | -105.7% |
| 2022 | $3M | $-213M | $-224M | $-176M | -382.0% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 2.78 | 233.66 | 329 | 616.29 |
| Operating Revenue | - | 2.78 | 233.66 | 329 | 616.29 |
| Cost Of Revenue | - | 0.26 | 14.13 | 38.49 | 100.71 |
| Gross Profit | - | 2.52 | 219.53 | 290.52 | 515.57 |
| Operating Expense | - | 220.84 | 198.90 | 248.59 | 392.25 |
| Research And Development | - | 125.35 | 76.19 | 94.29 | 160.22 |
| Selling General And Administration | - | 95.48 | 122.71 | 154.30 | 232.03 |
| Total Expenses | - | 221.10 | 213.03 | 287.08 | 492.96 |
| Operating Income | - | -218.32 | 20.63 | 41.93 | 123.32 |
| Total Operating Income As Reported | - | -218.32 | 20.63 | 41.93 | 123.32 |
| EBITDA | - | -213.11 | 26.10 | 49.90 | 134.36 |
| Normalized EBITDA | - | -213.11 | 26.10 | 49.90 | 134.36 |
| EBIT | - | -213.62 | 25.68 | 49.62 | 134.12 |
| Interest Expense | - | 10.19 | 12.62 | 24.03 | 26.73 |
| Net Interest Income | - | -10.19 | -12.62 | -24.03 | -26.73 |
| Other Non Operating Income Expenses | - | 4.70 | 5.04 | 7.69 | 10.79 |
| Other Income Expense | - | 4.70 | 5.04 | 7.69 | 10.79 |
| Interest Expense Non Operating | - | 10.19 | 12.62 | 24.03 | 26.73 |
| Net Non Operating Interest Income Expense | - | -10.19 | -12.62 | -24.03 | -26.73 |
| Pretax Income | - | -223.81 | 13.06 | 25.59 | 107.39 |
| Tax Provision | - | 0 | 0.39 | 2.21 | -339.79 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Net Income From Continuing And Discontinued Operation | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Net Income From Continuing Operation Net Minority Interest | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Net Income | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Net Income Common Stockholders | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Net Income Including Noncontrolling Interests | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Normalized Income | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Diluted NI Availto Com Stockholders | - | -223.81 | 12.67 | 23.38 | 447.18 |
| Basic Average Shares | - | 135.41 | 141.96 | 145.32 | 144.32 |
| Diluted Average Shares | - | 135.41 | 148.51 | 160.34 | 161.41 |
| Reconciled Depreciation | - | 0.52 | 0.42 | 0.28 | 0.24 |
| Reconciled Cost Of Revenue | - | 0.26 | 14.13 | 38.49 | 100.71 |
| General And Administrative Expense | - | 95.48 | 122.71 | 154.30 | 232.03 |
| Other Gand A | - | 64.05 | 97.78 | 122.92 | 183.98 |
| Salaries And Wages | - | 31.44 | 24.92 | 31.38 | 48.05 |
| Selling And Marketing Expense | 90.86 | 64.05 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| TG Therapeutics, Inc.this co. | TGTX | $6.2B | 13.88 | 9.58 | 69.0% | 47.51 |
| Alkermes plc | ALKS | $7.2B | 29.92 | 3.97 | 13.3% | 20.89 |
| Glaukos Corporation | GKOS | $7.1B | -38.08 | 10.89 | -28.6% | -49.02 |
| Protagonist Therapeutics, Inc. | PTGX | $6.6B | -50.79 | 10.75 | -21.2% | -41.39 |
| PTC Therapeutics, Inc. | PTCT | $5.9B | 8.58 |
| - |
| - |
| - |
| - |
| - |
| - |
| -332.5% |
| 7.46 |
| Teleflex Incorporated | TFX | $5.8B | -6.46 | 1.87 | -29.0% | 27.09 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.3B | 234.62 | 14.19 | 6.0% | 75.16 |
| Ligand Pharmaceuticals Incorporated | LGND | $4.7B | 37.99 | 4.65 | 12.2% | 25.35 |
| Indivior Pharmaceuticals, Inc. | INDV | $4.4B | 21.08 | -44.71 | -212.1% | 15.07 |
| Peer Median | - | 14.83 | 4.65 | -24.9% | 17.98 | |